Market Report by Application, Distribution Channel, Route of Administration and Company Analysis, 2025-2033" has been added ...

Ngenla, a hormone drug from partners Pfizer and Opko Health, is now FDA approved for treating children with growth hormone deficiency. The once-weekly injectable biologic will compete against an ...

CEO Albert Bourla highlighted Pfizer's strong execution in 2024, emphasizing the successful integration of Seagen, which has ...

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...

Pfizer Inc. (NYSE:PFE) will conduct an investor call on Tuesday to provide full-year 2025 financial guidance. Ahead of the call, Goldman Sachs has outlined its expectations for the guide and ...

Pfizer's acquisition of Seagen for $43 billion enhances its ADC technology, potentially expanding its oncology franchise and driving future growth. PFE's development of the oral GLP-1 receptor agonist ...

In the United States' healthcare sector, a new growth theme is emerging that nearly all companies want to capitalize on. Like artificial intelligence for technology stocks, weight loss drug ...